BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Large Scale Biology Corporation (LSBC) And Icon Genetics AG Announce Product Development Collaboration


10/19/2005 5:12:52 PM

VACAVILLE, CA and MUNICH, GERMANY -- (MARKET WIRE) -- 03/01/2005 -- Large Scale Biology Corporation (NASDAQ: LSBC) and Icon Genetics (ICON) announced today that they have entered into a collaborative agreement to co-develop a biopharmaceutical product for a major therapeutic market. Terms of the agreement were not disclosed. The alliance centers on the synergistic application of LSBC's and ICON's patented gene expression and biomanufacturing resources with the goal of developing and commercializing a defined therapeutic product, the manufacture of which by conventional technologies has proven difficult and expensive. Both ICON and LSBC biomanufacture their own and client-specified therapeutic proteins using non-food/fodder, non-recombinant plants in safe, contained production environments. The goal of the new collaboration is to accelerate development of a difficult-to-produce pharmaceutical by pooling the technical strengths of each company's plant-based platform.

Read at Market Wired

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES